Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy - PubMed (original) (raw)

. 2008 Apr;12(2):119-125.

doi: 10.1007/s10157-007-0011-8. Epub 2008 Jan 5.

Affiliations

• PMID: 18175064
• DOI: 10.1007/s10157-007-0011-8

Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy

Shinya Kobayashi et al. Clin Exp Nephrol. 2008 Apr.

Abstract

Background: Serotonin (5-HT) is involved in vascular inflammation and atherosclerogenesis. Serum 5-HT concentrations are elevated in diabetes, and 5-HT is involved in diabetic vasculopathies. Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, has renoprotective effects, but its effect in diabetic nephropathy is not elucidated. The aim of this study was to examine the effects of sarpogrelate on endothelial dysfunction in rats with streptozotocin (STZ)-induced diabetes.

Methods: Rats with STZ-induced diabetes were either untreated or treated with sarpogrelate (30 mg/kg P.O.) for 8 weeks. At the end of the experiment, we measured urinary albumin excretion, serum adiponectin concentration and platelet-derived microparticles. Intraglomerular coagulation was detected by immunostaining for platelets. Production of renal reactive oxygen species (ROS) and nitric oxide (NO) was investigated by confocal laser microscopy and used as an index of glomerular endothelial dysfunction.

Results: Diabetic nephropathy was associated with enhanced production of ROS and diminished bioavailable NO in the glomeruli. Treatment with sarpogrelate improved ROS/NO imbalance in glomeruli, suppressed platelet aggregation in glomeruli, reduced platelet-derived microparticles, increased serum adiponectin level and reduced the level of albuminuria, compared with non-treated diabetic rats.

Conclusions: Our results indicate that sarpogrelate improves endothelial function in rats with STZ-induced diabetes through a reduction of glomerular platelet activation and an increase in serum adiponectin concentrations and suggest that sarpogrelate is potentially useful for the treatment of diabetic nephropathy.

PubMed Disclaimer

Similar articles

• Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft.
  Kodama A, Komori K, Hattori K, Yamanouchi D, Kajikuri J, Itoh T. Kodama A, et al. J Vasc Surg. 2009 May;49(5):1272-81. doi: 10.1016/j.jvs.2008.11.071. Epub 2009 Feb 23. J Vasc Surg. 2009. PMID: 19233592
• Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.
  Umrani DN, Bodiwala DN, Goyal RK. Umrani DN, et al. Mol Cell Biochem. 2003 Jul;249(1-2):53-7. Mol Cell Biochem. 2003. PMID: 12956398
• The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats.
  Hiragushi K, Wada J, Eguchi J, Matsuoka T, Yasuhara A, Hashimoto I, Yamashita T, Hida K, Nakamura Y, Shikata K, Minamino N, Kangawa K, Makino H. Hiragushi K, et al. Kidney Int. 2004 Feb;65(2):540-50. doi: 10.1111/j.1523-1755.2004.00407.x. Kidney Int. 2004. PMID: 14717924
• 5-hydroxytryptamine and its receptors in systemic vascular walls.
  Machida T, Iizuka K, Hirafuji M. Machida T, et al. Biol Pharm Bull. 2013;36(9):1416-9. doi: 10.1248/bpb.b13-00344. Biol Pharm Bull. 2013. PMID: 23995652 Review.
• Workshop: endothelial cell dysfunction leading to diabetic nephropathy : focus on nitric oxide.
  Goligorsky MS, Chen J, Brodsky S. Goligorsky MS, et al. Hypertension. 2001 Feb;37(2 Pt 2):744-8. doi: 10.1161/01.hyp.37.2.744. Hypertension. 2001. PMID: 11230367 Review.

Cited by

• Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.
  Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, Haruna Y, Horike H, Sasaki T, Kashihara N. Satoh M, et al. Nephrol Dial Transplant. 2008 Dec;23(12):3806-13. doi: 10.1093/ndt/gfn357. Epub 2008 Jul 2. Nephrol Dial Transplant. 2008. PMID: 18596126 Free PMC article.
• Improvement of Cardiac Function and Subcellular Defects Due to Chronic Diabetes upon Treatment with Sarpogrelate.
  Tappia PS, Elimban V, Shah AK, Goyal RK, Dhalla NS. Tappia PS, et al. J Cardiovasc Dev Dis. 2024 Jul 9;11(7):215. doi: 10.3390/jcdd11070215. J Cardiovasc Dev Dis. 2024. PMID: 39057635 Free PMC article.
• Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice.
  Lee ES, Lee MY, Kwon MH, Kim HM, Kang JS, Kim YM, Lee EY, Chung CH. Lee ES, et al. PLoS One. 2017 Jun 22;12(6):e0179221. doi: 10.1371/journal.pone.0179221. eCollection 2017. PLoS One. 2017. PMID: 28640832 Free PMC article.
• Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.
  Wang Y, Chen LM, Liu ML. Wang Y, et al. Acta Pharmacol Sin. 2014 Apr;35(4):433-43. doi: 10.1038/aps.2013.188. Epub 2014 Mar 10. Acta Pharmacol Sin. 2014. PMID: 24608676 Free PMC article. Review.
• Enteroendocrine cells and gut hormones as potential targets in the crossroad of the gut-kidney axis communication.
  Nery Neto JAO, Yariwake VY, Câmara NOS, Andrade-Oliveira V. Nery Neto JAO, et al. Front Pharmacol. 2023 Oct 19;14:1248757. doi: 10.3389/fphar.2023.1248757. eCollection 2023. Front Pharmacol. 2023. PMID: 37927592 Free PMC article. Review.

References

1. 1. Am J Physiol Renal Physiol. 2005 Jun;288(6):F1144-52 - PubMed
2. 1. Kidney Int. 1998 Oct;54(4):1083-92 - PubMed
3. 1. J Leukoc Biol. 1994 May;55(5):567-73 - PubMed
4. 1. Diabetes Care. 2003 Feb;26(2):285-9 - PubMed
5. 1. Metabolism. 2007 Oct;56(10):1363-71 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information